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Abstract
Background: We report the successful treatment of the patient with osimertinib 80 mg/day following disease progression
and a discordance in the detection of a mechanism of resistance epithelial growth factor receptor (EGFR) T790 M between
liquid biopsy and tissue biopsy methods.
Case presentation: A 57-year-old Hispanic male patient initially diagnosed with an EGFR 19 deletion positive lung
adenocarcinoma and clinically responded to initial erlotinib treatment. The patient subsequently progressed on
erlotinib 150 mg/day and repeat biopsies both tissue and liquid were sent for next-generation sequencing (NGS).
A T790 M EGFR mutation was detected in the blood sample using a liquid biopsy technique, but the tissue
biopsy failed to show a T790 M mutation in a newly biopsied tissue sample. He was then successfully treated
with osimertinib 80 mg/day, has clinically and radiologically responded, and remains on osimertinib treatment
after 10 months.
Conclusions: Second-line osimertinib treatment, when administered at 80 mg/day, is both well tolerated and
efficacious in a patient with previously erlotinib treated lung adenocarcinoma and a T790 M mutation detected
by liquid biopsy.
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Background
Non-Small Cell Lung Cancer (NSCLC) is a devastating
disease and is the leading cause of cancer-related death
worldwide. However, the treatment options for NSCLC
have evolved dramatically in the last decade and NSCLC
has become instrumental in advancing the new age of
personalized medicine where standard platinum doublet
chemotherapy is substituted by tyrosine kinase inhibitors
(TKIs) when patients are tested and diagnosed with
actionable mutations. The specificity of the disease and
the histological differences in individual cancer types,
such as lung adenocarcinoma, no longer dictate the
clinical outcome and potential treatment options, but it
is really the omic-architecture of individual patients that
becomes the driver of treatment for targeted therapy as
well as immunotherapy. The genomic layout of adeno-
carcinomas is continuously being redefined with a myr-
iad of genetic alterations, such as mutations in EGFR,
MET, and BRAF, translocations in ALK and ROS1,
detected and present in the TCGA dataset [1]. For
example, approximately 10% of patients with NSCLC in
the US have tumor involving the epidermal growth fac-
tor receptor (EGFR) somatic activating mutations [2].
Exon 19 deletion mutations and single-point substitution
mutation L858R in exon 21 are considered “classic”
mutations that are sensitive to EGFR TKIs and account
for 90% of all EGFR mutations in NSCLC [3, 4]. The
presence of these mutations in select NSCLC patients
showed dramatic TKI response rates (RRs) of 68% with a
mean progression-free survival (PFS) and time to pro-
gression of 12 months [5–7].
Based on this evidence, EGFR testing and EGFR TKIs
have become a staple of lung cancer clinical treatment
and since then the College of American Pathologists,
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and the Association for Molecular Pathology have stan-
dardized the testing guidelines for selection of lung can-
cer patients for EGFR inhibitors as well as the methods
of testing, such as real-time polymerase chain reaction
(PCR) and next-generation sequencing (NGS) [8].
Nevertheless, almost all patients who initially respond to
EGFR inhibitors in NSCLC eventually develop acquired
resistance (AR). So far, it is known that a secondary
T790 M mutation in exon 20 of the EGFR gene accounts
for approximately 50% of cases of AR, alongside other
less understood mechanisms of resistance [9]. The FDA
has recently approved Osimertinib for the treatment of
patients with metastatic T790 M mutation-positive non-
small cell lung cancer (NSCLC) based on the evidence
of the AURA3 trial where progression-free survival
benefit was observed in both progressive NSCLC follow-
ing first-line EGFR TKI therapy and EGFR T790 M
mutation-positive NSCLC identified by the cobas EGFR
mutation test [10, 11]. A recent study on the detection
of T790 M by Tumor Biopsy versus Noninvasive Blood-
based methods showed that the overall T790 M muta-
tion positive rate was approximately 50% consistent with
previous biopsy series [12]. In this case report, we
present a male patient diagnosed with EGFR positive
lung adenocarcinoma that partially responded to erloti-
nib, but eventually progressed. Upon progression the pa-
tient’s blood and tissue samples were tested using NGS.
The tissue biopsy test failed to detect a T790 M muta-
tion, while the liquid biopsy test successfully showed a
T790 M resistance mutation present in the patient’s
blood. The patient was treated with osimertinib with
notable clinical and radiological response. The patient
continues to be treated successfully with osimertinib and
will remain on osimertinib treatment after 6 months.
Case presentation
A 57 year old Hispanic male who smoked for one year ini-
tially presented with lower back pain that eventually pro-
gressed to increasing upper back pain. An orthopedic
surgeon performed an MRI scan which revealed multiple
metastases to the thoracic spine. An initial CT scan
revealed a right lung mass and a subsequent bronchos-
copy revealed a non-small cell lung cancer consistent with
poorly differentiated adenocarcinoma. For first line ther-
apy, he received one cycle of carboplatin and docetaxel
which was tolerated well with only mild nausea. He com-
pleted four cycles of chemotherapy and a pathology report
identified an EGFR exon 19 deletion. The patient started
on erlotinib, an EGFR inhibitor, at 150 mg capsule per day
taken by mouth without food or on an empty stomach 1 h
before or 2 h after food. Patient was also advised to avoid
sunlight while on therapy due to skin toxicity. He toler-
ated it well and had clinically responsive disease as well as
a decrease in primary mass from 5 cm to 2.8 cm on CT
scan for over a year until he had started developing wors-
ening back pain and complications caused by papulopust-
ular lesions as well as paronychia and xerosis. He also
developed a Klebsiella folliculitis which necessitated dis-
continuation of the trimethoprim-sulfamethoxazole that
he had been taking for the acneiform lesions and a
brief course of ciprofloxacin that had led to the reso-
lution of the papulopustular eruption.
He also started to have persistent elevation of carci-
noembryonic antigen (CEA) level from 5.4 ng/ml rising
steadily to 13.4 ng/ml and eventually rising exponentially
to 24.3 ng/ml but continued on erlotinib, dose reduced to
100 mg one capsule per day, due to stable MRI scans. Pa-
tient was evaluated for a possible surgery on the spine but
was unfortunately not a surgical candidate. A CT of the
chest with and without contrast reported significant pri-
mary site progression of bilateral varying size small lung
nodular lesions, consistent with metastatic. The right
infrahilar nodular mass also increased from 2.1 × 1.5 cm
to 2.8 × 2.4 cm. Clinically he was progressing and he
underwent a fine needle biopsy on the right lung mass
and pathology reported moderately differentiated meta-
static adenocarcinoma. Tissue was sent for molecular test-
ing via next generation sequencing with CLIA-certified
Foundation Medicine multi-gene assay and a blood draw
was performed for liquid biopsy utilizing the Guardant
360 platform, which are both comparable to the cobas
EGFR tissue test and plasma ctDNA test in the AURA3
trial. While awaiting the results, erlotinib was stopped and
he was given one cycle of carboplatin AUC 5 and peme-
trexed 500 mg/m2. Soon afterward liquid biopsy report
returned and was shown to be positive for a T790 M mu-
tation that is a mechanism of acquired resistance to EGFR
tyrosine kinase inhibitor (TKI) therapy. Liquid biopsy util-
izing the Guardant 360 platform also detected ten other
mutations; EGFR exon 19 deletion, TP53 R196Q muta-
tion, FGFR3 L406R mutation, VHL S65A mutation,
RHOA E47K mutation, APC D1512N mutation, NTRK1
T360 T mutation, PDGFRA I497I mutation, FGFR2
E767K mutation, BRCA1 E962K mutation.
Based on the T790 M mutation he was started on
osimertinib, at 80 mg tablet per day taken by mouth, and
tolerated it well. A few weeks into the osimertinib treat-
ment the tissue biopsy test reported five mutations, CDK4
amplification, MDM2 amplification, FRS2 amplification,
GLI1 amplification as well as the EGFR exon 19 deletion
and nine variants of unknown significance; EP300
M2372 V, GNAS P345R and P349_I357del, IRF4 A341V,
MED12 Q2120_Q2121 >HQQQQQ, MET D1373H, MLL
A53V, SMARCA4 A1186_Q1187del, SOX9 A481T, SPTA1
R1077C. However, tissue biopsy test did not detect a
T790 M mutation showing discordance between the tissue
biopsy and the liquid biopsy. He continued on osimertinib
treatment and a Chest CT (Fig. 1) scan ten months into the
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treatment showed a decrease in the right lower lobe mass
and numerous bilateral pulmonary nodules had either sig-
nificant decrease or resolved. There were also stable wide-
spread osseous metastases. This was noted to be a partial
response and it was decided that the patient will continue
on osimertinib. He has tolerated osimertinib well with only
symptoms of a mild rash and low platelets which quickly
stabilized without dose adjustment.
Discussion and conclusions
In this study, the treatment plan for the patient could
have been potentially undermined by the NGS technol-
ogy and lack of standardization of detection methods for
EGFR mechanisms of resistance. This shows that tumor
heterogeneity plays an important role not only thera-
peutically but is reliant on clinical efficacy to do what is
beneficial for the patient based on the evidence of a
blood-based T790 M detection. Our case report reflects
not only a molecular switch within the tumor, but also
highlights the discordance in one sample and not the
other. As can be appreciated, the patient initially had
L858R EGFR abnormality and responded to erlotinib.
However, upon clinical and radiological progression, the
tumor biopsy of the lung lesion still showed the original
L858R EGFR abnormality, but did not detect the classic
T790 M mutation of acquired resistance. Interestingly,
the liquid biopsy revealed the classic T790 M EGFR
mutation along with the original EGFR mutation. The
Fig. 1 Chest CT Scans of Patient on Osimertinib Treatment. a Chest CT Scan Prior to Osimertinib Treatment. b CT Chest w/Abdomen wwo/Pelvis
w Contrast Scan Post-Osimertinib Treatment
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absence of a T790 M mutation in tumor tissue may be
explained by the limited tissue available from the lung as
well as inter- and intra-tumor heterogeneity where the
tissue biopsy does not give a full viewpoint of the entire
tumor or the genetic heterogeneity of metastatic disease.
Meanwhile the detection of a T790 M mutation in the li-
quid biopsy may be due to the nature of metastatic dis-
ease and the diverse circulating tumor DNA population
that represents the overall mixed heterogeneity of the
disease rather than limited to a small tissue sample from
a single site. Based on this, we were able to make intelli-
gent clinical decision to start osimertinib and the patient
is responding (thus far, up to 10 months and continu-
ing). Figure 2 summarizes the patient’s oncologic history
as a timeline.
In the past, we had poorly utilized biomarkers such as
CEA and CA125 to determine the response or progression
to therapy [13]. More recently, we have begun to deter-
mine the role of tumor tissue genomic biomarkers and
circulating biomarkers. The molecular diagnostic field has
come far over the past few years and the advent of liquid
biopsies offers an opportunity to circumvent invasive tis-
sue biopsies at the time of each disease progression. Li-
quid biopsies offer flexibility and repeatability for the
patient that tissue biopsies do not due to high costs, high
morbidity, or lack of available tissue. Though the list of
currently available approved targeted therapies remains
limited, only recently the FDA granted accelerated ap-
proval to the EGFR TKI osimertinib for patients with ad-
vances T790 M mutation-positive NSCLC based on the
evidence of two-single arm studies with RRs between 57–
61% [14, 15]. Consequently, in a recent study, we showed
that NSCLC patient assessment of targeted therapies
using commercially available ctDNA assays had a high
concordance of 80% between paired tissue and blood for
truncal oncogenic drivers and patients with biomarkers
identified in plasma had expected progression free-
survival (PFS) [16]. Though there may be no difference in
progression-free survival between the liquid-positive and
tissue-positive groups, there is still a necessity to consider
this as a novel molecular diagnostic tool that requires less
intervention and can possibly in the future be widely used
to treat tumor heterogeneity over time in advanced stage
NSCLC [17]. Therefore, we would recommend that ana-
lysis of biomarkers be routinely considered in mechanisms
of resistance as well in the initial molecular diagnosis of
advanced stage adenocarcinoma of the lung [17]. This case
reflects the discordance between tissue and liquid biopsy.
As we go forward in decision making, we might have to
utilize both diagnostics to arrive at a meaningful clinical
decision.
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